001016952 001__ 1016952
001016952 005__ 20240213111715.0
001016952 0247_ $$2doi$$a10.3233/JAD-221153
001016952 0247_ $$2ISSN$$a1387-2877
001016952 0247_ $$2ISSN$$a1875-8908
001016952 0247_ $$2pmid$$a37182873
001016952 0247_ $$2WOS$$aWOS:001006111900010
001016952 037__ $$aFZJ-2023-03860
001016952 082__ $$a610
001016952 1001_ $$0P:(DE-HGF)0$$aRakuša, Elena$$b0$$eCorresponding author
001016952 245__ $$aSporadic Use of Antibiotics in Older Adults and the Risk of Dementia: A Nested Case–Control Study Based on German Health Claims Data
001016952 260__ $$aAmsterdam$$bIOS Press$$c2023
001016952 3367_ $$2DRIVER$$aarticle
001016952 3367_ $$2DataCite$$aOutput Types/Journal article
001016952 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704981737_7514
001016952 3367_ $$2BibTeX$$aARTICLE
001016952 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001016952 3367_ $$00$$2EndNote$$aJournal Article
001016952 500__ $$aBitte Post-print ergänzen
001016952 520__ $$aBackground: Antibiotics for systemic use may increase the risk of neurodegeneration, yet antibiotic therapy may be able to halt or mitigate an episode of neurodegenerative decline.Objective: To investigate the association of sporadic use of antibiotics and subsequent dementia risk (including Alzheimer's disease).Methods: We used data from the largest public health insurance fund in Germany, the Allgemeine Ortskrankenkasse (AOK). Each of the 35,072 dementia cases aged 60 years and older with a new dementia diagnosis during the observation period from 2006 to 2018 was matched with two control-patients by age, sex, and time since 2006. We ran conditional logistic regression models for dementia risk in terms of odds ratios (OR) as a function of antibiotic use for the entire antibiotic group and for each antibiotic subgroup. We controlled for comorbidities, need for long-term care, hospitalizations, and nursing home placement.Results: Antibiotic use was positively associated with dementia (OR = 1.18, 95% confidence interval (95% CI):1.14-1.22), which became negative after adjustment for comorbidities, at least one diagnosis of bacterial infection or disease, and covariates (OR = 0.93, 95% CI:0.90-0.96). Subgroups of antibiotics were also negatively associated with dementia after controlling for covariates: tetracyclines (OR = 0.94, 95% CI:0.90-0.98), beta-lactam antibacterials, penicillins (OR = 0.93, 95% CI:0.90-0.97), other beta-lactam antibacterials (OR = 0.92, 95% CI:0.88-0.95), macrolides, lincosamides, and streptogramins (OR = 0.88, 95% CI:0.85-0.92), and quinolone antibacterials (OR = 0.96, 95% CI:0.92-0.99).Conclusion: Our results suggest that there was a decreased likelihood of dementia for preceding antibiotic use. The benefits of antibiotics in reducing inflammation and thus the risk of dementia need to be carefully weighed against the increase in antibiotic resistance.
001016952 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x0
001016952 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001016952 7001_ $$0P:(DE-HGF)0$$aFink, Anne$$b1
001016952 7001_ $$0P:(DE-Juel1)177986$$aTamgüney, Gültekin$$b2$$ufzj
001016952 7001_ $$0P:(DE-HGF)0$$aHeneka, Michael T.$$b3
001016952 7001_ $$0P:(DE-HGF)0$$aDoblhammer, Gabriele$$b4
001016952 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-221153$$gVol. 93, no. 4, p. 1329 - 1339$$n4$$p1329 - 1339$$tJournal of Alzheimer's disease$$v93$$x1387-2877$$y2023
001016952 8564_ $$uhttps://juser.fz-juelich.de/record/1016952/files/Rakusa%20et%20al%202023%20Sporadic%20Use%20of%20Antibiotics-1.pdf
001016952 909CO $$ooai:juser.fz-juelich.de:1016952$$pVDB
001016952 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177986$$aForschungszentrum Jülich$$b2$$kFZJ
001016952 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
001016952 9141_ $$y2023
001016952 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2022$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
001016952 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
001016952 920__ $$lyes
001016952 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
001016952 980__ $$ajournal
001016952 980__ $$aVDB
001016952 980__ $$aI:(DE-Juel1)IBI-7-20200312
001016952 980__ $$aUNRESTRICTED